Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research[1][2].
Lucatumumab (0.001-10 μg/mL; 4 h; 37 ℃) inhibit B-cell chronic lymphocytic leukemia (B-CLL) growth by ADCC-mediated cell lysis, with the average maximal lysis of B-CLL cells of 49%[1].
Lucatumumab (0.1-10 μg/mL; 3 d) inhibits CD40L-induced signaling and viability of B-CLL cells[1].
Lucatumumab (10 μg/mL; 24 h) inhibits cytokine secretion by B-CLL cells[1].
Cell Viability Assay[1]
| Cell Line: | B-cell chronic lymphocytic leukemia (B-CLL) |
| Concentration: | 0.001 to 10 μg/mL |
| Incubation Time: | 72 hours; 37 ℃ |
| Result: | Inhibited B-CLL growth with an ED50 of 14 pM and a average maximal lysis of B-CLL cells of 49%. |